Skip to main content

Time in Range

What's new

Two studies recently published on the Control-IQ and MiniMed 780G systems show that closed-loop automated insulin delivery significantly improves Time in Range. Continue Reading »

A fully virtual six-month clinical trial is recruiting 300 people with type 1 and type 2 diabetes who are interested in trying continuous glucose monitoring (CGM) with personal support. The study will determine how access to virtual diabetes care with CGM impacts Time in Range (TIR). Continue Reading »

Emerging evidence shows that variability in your A1C level may put you at a higher risk of stroke and heart disease.  Continue Reading »

Zegalogue emergency glucagon comes as a pre-filled injection or auto-injector pen and can be used to treat severe hypoglycemia quickly.  Continue Reading »

Insulet’s Omnipod 5 automated insulin delivery system was shown to be effective, safe, and easy to use for adults, teens, and children with type 1 diabetes. Early results from a very small group also show Omnipod 5 to be particularly helpful for people with type 2 diabetes. ​ Continue Reading »

This clinical trial is currently recruiting. Families will participate in weekly sessions that focus on topics related to diabetes distress and parent-teen communication, with the hopes of improving Time in Range and lowering A1C levels in the teen with type 1 diabetes.  Continue Reading »

Research shows that changes in Time in Range (TIR) affect your mood and that continuous glucose monitoring may help people with diabetes achieve better emotional health.   Continue Reading »

GMI provides an estimated A1C level based on continuous glucose monitoring data and can avoid some of the limitations of A1C tests. A recent study compared actual A1C levels with GMI to see how the two compared in the real world. Continue Reading »

Pages